Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchEnsitrelvirEnsitrelvir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Ensitrelvir for COVID-19: real-time meta analysis of 3 studies

@CovidAnalysis, February 2024, Version 9V9
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mukae (DB RCT) 45% 0.55 [0.37-0.81] viral load 14 (n) 14 (n) Improvement, RR [CI] Treatment Control Mukae (DB RCT) 36% 0.64 [0.41-1.00] viral load 15 (n) 14 (n) Mukae (DB RCT) 45% 0.55 [0.34-0.90] viral time 15 (n) 14 (n) Mukae (DB RCT) 44% 0.56 [0.35-0.92] viral time 13 (n) 14 (n) Mukae (DB RCT) 54% 0.46 [0.05-4.38] viral+ 1/12 2/11 Mukae (DB RCT) -10% 1.10 [0.22-5.51] viral+ 3/15 2/11 Mukae (DB RCT) 80% 0.20 [0.01-3.80] viral+ 0/13 2/13 Mukae (DB RCT) 54% 0.46 [0.05-4.53] viral+ 1/14 2/13 Mukae (DB RCT) 54% 0.46 [0.10-2.12] viral+ 2/14 4/13 Mukae (DB RCT) 90% 0.10 [0.01-0.85] viral+ 0/15 4/13 Mukae (DB RCT) 80% 0.20 [0.05-0.75] viral+ 2/14 10/14 Mukae (DB RCT) 63% 0.37 [0.15-0.92] viral+ 4/15 10/14 Mukae (DB RCT) 9% 0.91 [0.59-1.40] viral+ 10/14 11/14 Mukae (DB RCT) -10% 1.10 [0.79-1.55] viral+ 13/15 11/14 Mukae (DB RCT) 9% 0.91 [0.76-1.08] improv. 116 (n) 111 (n) Mukae (DB RCT) 17% 0.83 [0.69-0.99] improv. 114 (n) 111 (n) Mukae (DB RCT) 32% 0.68 [0.56-0.82] viral time 113 (n) 108 (n) Mukae (DB RCT) 44% 0.56 [0.42-0.75] viral time 113 (n) 108 (n) SCORPIO-SR Yotsuyan.. (DB RCT) -1% 1.01 [0.06-16.1] hosp. 1/595 1/600 SCORPIO-SR Yotsuyan.. (DB RCT) 67% 0.33 [0.01-8.15] hosp. 0/603 1/600 SCORPIO-SR Yotsuyan.. (DB RCT) 11% 0.89 [0.71-1.11] recov. time 577 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 10% 0.90 [0.68-1.19] recov. time 582 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 18% 0.82 [0.67-1.00] recov. time 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 19% 0.81 [0.67-0.98] recov. time 336 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 13% 0.87 [0.65-1.17] recov. time 577 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 10% 0.90 [0.49-1.68] recov. time 582 (n) 572 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 13% 0.87 [0.74-1.02] recov. time 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 16% 0.84 [0.70-1.01] recov. time 336 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 49% 0.51 [0.34-0.76] viral load 579 (n) 589 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 49% 0.51 [0.34-0.76] viral load 592 (n) 589 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 59% 0.41 [0.24-0.69] viral load 330 (n) 321 (n) SCORPIO-SR Yotsuyan.. (DB RCT) 59% 0.41 [0.24-0.69] viral load 336 (n) 321 (n) Ensitrelvir COVID-19 outcomes c19early.org February 2024 Favors ensitrelvir Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit